Table 1.
Consequence of complement deficiency on outcome of neurodegenerative disease.
| Model | Deficiency | Consequence | Reference | |
|---|---|---|---|---|
| TBI | Traumatic brain cryoinjury | C3 | Reduced pathology | (51) |
| Controlled cortical impact | C3 | No effect | (52) | |
| Controlled cortical impact | C4 | Improved function | (52) | |
| Traumatic brain cryoinjury | C5 | Reduced pathology | (51) | |
| Closed head injury | CR2 | Improved function | (53) | |
| Controlled cortical impact | C1q | No effect | (52) | |
| Closed head injury | FB | Reduced pathology | (54) | |
| SCI | T9 contusion | C1q | Improved function | (55) |
| Contusion induced injury | FB | Improved function | (56) | |
| Weight drop | C3 | Improved function | (57) | |
| Contusion injury | C5a | Improved function | (58) | |
| Contusion induced injury | CD59 | Impaired recovery, increased injury | (56) | |
| AD | Tg2576 | C1q | Ameliorates synapse loss | (59) |
| oAβ injection | C1q | Ameliorates synapse loss | (60) | |
| APP/PS1 | C3 | Ameliorates synapse loss | (60) | |
| J20 APP | C3 | Exacerbated pathology | (61) | |
| oAβ injection | CR3 | Ameliorates synapse loss | (60) | |
| APP/PS1 | C3 | Improved function | (62) | |
| ALS | SOD1G37R | C1q | No effect | (63) |
| SOD1G37R | C3 | No effect | (63) | |
| SOD1G37R | C4 | No effect | (64) | |
| SOD1G37R | C5aR1 | Extended survival | (65) | |
| HD | R6/2 | C3 | No effect | (66) |
| PD | MPTP induction of PD | C3 | No effect | (67) |
| MPTP induction of PD | C1q | No effect | (68) | |
| Paraquat/maneb induction of PD | CR3 | Reduced dopaminergic neurodegeneration | (69) |
TBI, Traumatic brain injury; SCI, spinal cord injury; AD, Alzheimer's disease; ALS, Amyotrophic lateral sclerosis; PD, Parkinson's disease; HD, Huntington's disease.